Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Androgenetic alopecia is the main reason people lose hair, and while some think it's normal, others find it abnormal and want treatment.

AGA patients have higher rates of metabolic syndrome and carotid atheromatosis, suggesting early screening and prevention is important.

In this study, researchers found that stress is linked to androgenic alopecia in both male and female patients, with an increasing number of female patients in their forties experiencing the condition.

This study developed a new neural network model (AA-GAN-AB-MTEDeep) to enhance Alopecia Areata classification using synthetic scalp images, achieving an accuracy of 96.94%.

This research review discusses the potential link between androgenetic alopecia and increased cardiovascular risk but does not report any new experimental findings.

This review discusses the role of Prostaglandin D2 and its synthase in androgenetic alopecia but reports no new clinical findings, suggesting pathways for future therapeutic development.

This article reviews recent advancements in understanding and treating androgenetic alopecia, focusing on new genetic insights, stem cell roles, and diagnostic tools, without reporting new clinical results.

In this consensus document, 34 dermatologists from the Spanish Trichology Society used the Delphi method to create comprehensive recommendations for managing androgenetic alopecia, offering guidance based on expert opinion and available scientific evidence to assist clinicians in routine treatment.

ALDOA levels drop in hair cells during hair loss.

This article reviews the classification history of androgenic alopecia and highlights the need for further research to find effective hair growth medications.

This retrospective study of 1604 alopecia areata cases reported 13 instances of a potentially new hair regrowth pattern, termed the "androgenetic-like pattern".

In this study, UVFD and sUVRD techniques revealed distinctive characteristics of GD lesions, suggesting that GD might be more common in younger individuals and females than previously thought, possibly due to underdiagnosis. Incorporating dermatoscopy in exams may help improve GD detection and management.

This study discusses the physiopathogeny, clinical manifestations, and treatment objectives of androgenetic alopecia without reporting new clinical findings.

This review highlights that while finasteride and minoxidil effectively treat androgenetic alopecia, emerging options like dutasteride, mesotherapy, androgen blockers, and red LED therapy show promising results, especially when used in combination, though further research is needed for standardization and safety confirmation.

This study found that moderate to severe androgenetic alopecia is an independent predictor of increased mortality risk from diabetes mellitus and heart disease in both sexes.

This review discusses the role of androgen hormones in the pathophysiology of childhood androgenetic alopecia and reports no clinical results.

This study found that males with androgenetic alopecia had a higher risk of coronary artery disease, with significant differences in several lipid and blood pressure markers compared to controls.

This review discusses current and emerging treatments for androgenetic alopecia, covering mechanisms, efficacy, and safety of both androgen-targeted and non-androgen-targeted approaches, but reports no new clinical results.

This review compiles existing information on the pathogenesis of androgenetic alopecia, highlighting its genetic, hormonal, and environmental factors, but reports no new clinical findings.

A substance called prostaglandin D2 is found more in bald scalps and it stops hair from growing. Blocking its receptor could potentially treat hair loss.

This abstract provides no results, as it only notes Sharon Keene's professional role and describes a non-blood test for AGA genetics.

This study found that dutasteride increased hair growth metrics significantly more than finasteride in Korean men with AGA, but a meta-analysis suggests no overall significant efficacy difference between the two drugs.

This review discusses the physiopathology of androgenetic alopecia and evaluates various traditional and emerging treatments, reporting no new clinical results but highlighting the need for enhanced treatment strategies.

This review discusses current treatment options for androgenetic alopecia, noting that most lack robust evidence for efficacy and safety, highlighting the need for more comprehensive studies.

In this study, higher expression of PEDF was observed in hair follicles from balding regions in AGA patients, suggesting that targeting PEDF could be a promising approach for treating androgenetic alopecia.

In this review, researchers explored key mechanisms underlying androgenetic alopecia, revealing how hormonal, oxidative, inflammatory, and lipid dysregulation suppress hair growth pathways and suggesting new therapeutic targets such as DP2 antagonists and microbiome modulators.

In this study, depression was more common among women with androgenetic alopecia, while men showed higher levels of anxiety, aggressiveness, and a lack of adherence to treatment.

This article reviews treatments for androgenetic alopecia and reports no new clinical findings; it highlights interest in therapies like platelet-rich plasma and laser therapy, indicating potential for further research.

A new treatment using special microneedles and a nitric oxide-releasing drug could improve hair growth and be more convenient for people with hair loss.

This letter to the editor discusses patient perspectives on androgenetic alopecia treatment at a tertiary dermatology center in Singapore, though results or specific findings are not reported in the abstract.